Our technologies
Targeted therapy: PTX-100
PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme, thereby disrupting the oncogenic Ras pathway. PTX-100 is now in a Phase 1b expansion cohort study in T cell lymphomas, where it is showing encouraging efficacy and safety. The US FDA has granted PTX-100 Orphan Drug Designation for all T cell lymphomas.
Cell therapy: CellPryme
CellPryme is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. CellPryme-M can be briefly added to standard manufacturing processes. CellPryme-A is used as an adjuvant alongside cellular immunotherapy.
Cell therapy: OmniCAR
The OmniCAR platform seeks to overcome the challenges of conventional CAR-T therapy including manufacturing, safety and reliability. OmniCAR is a modular, universal CAR platform based on technology licensed from UPenn and Oxford University. It allows unprecedented control and flexibility over current generation CAR-T approaches.
Recent investor briefing
Register for an upcoming briefing or watch a previous session.
OUR PIPELINE
We have a diversified pipeline of later stage and emerging assets developed with world-leading partners including Yale, UPenn, Oxford and Moffitt and Peter MacCallum Cancer Centre.
INVESTOR PORTAL
Here you will find ASX announcements and share price data, along with other key company information. You can also subscribe for email updates and online investor briefings to engage with management directly.
STAY UP TO DATE
Register your details to receive company updates from Prescient Therapeutics
Media
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
5th Sep 2024
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
5th Sep 2024
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…
Prescient Therapeutics: PTX-100 Phase 2 coming soon
29th Aug 2024
Prescient Therapeutics update report 2024 08 29
Prescient Therapeutics appoints accomplished medical professional Dr Gavin Shepherd as a director
4th Jul 2024
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF), a clinical-stage oncology company developing personalised therapies for cancer, has appointed accomplished medical professional Dr Gavin Shepherd as an independent…
Prescient Therapeutics: Current Developments in Cancer Treatment
31st May 2024
Prescient Therapeutics, an ASX-listed company, is engaged in the development of drugs targeting various forms of cancer, with a specific focus on blood cancers that…